07:19 AM EDT, 07/24/2026 (MT Newswires) -- LIB Therapeutics' hypercholesterolaemia and mixed dyslipidaemia drug Lyrokaul was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use. The biopharmaceutical company's drug, which is available as a solution for pre-filled syringes, can reduce the levels of serum LDL-cholesterol in patients whose cholesterol is not under control, according to a Friday notice. The opinion will be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorization.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.